

Accepted Manuscript

Title: Crosstalk Between Insulin and Dopamine Signaling: A Basis for the Metabolic Effects of Antipsychotic Drugs

Author: Abigail I. Nash

PII: S0891-0618(16)30069-2
DOI: <http://dx.doi.org/doi:10.1016/j.jchemneu.2016.07.010>
Reference: CHENEU 1426



To appear in:

Received date: 29-4-2016
Revised date: 14-7-2016
Accepted date: 27-7-2016

Please cite this article as: Nash, Abigail I., Crosstalk Between Insulin and Dopamine Signaling: A Basis for the Metabolic Effects of Antipsychotic Drugs. *Journal of Chemical Neuroanatomy* <http://dx.doi.org/10.1016/j.jchemneu.2016.07.010>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title: Crosstalk Between Insulin and Dopamine Signaling: A Basis for the Metabolic Effects of Antipsychotic Drugs

Abigail I. Nash, National Institutes of Health, National Institute of Mental Health, Bethesda, MD 20892

contact info: abigail.nash@nih.gov

Highlights

Dopamine and insulin signaling systems have a reciprocal regulatory relationship.

Schizophrenia and its treatment impart a high risk for obesity and hyperinsulinemia

Short-term antagonism of dopamine D2 receptors increases insulin secretion.

Insulin increases dopamine reuptake acutely but downregulates it chronically.

Altered dopamine signaling may contribute to the pathogenesis of metabolic syndrome.

Abstract

In the setting of rising rates of obesity and metabolic syndrome, characterized in part by hyperinsulinemia, it is increasingly important to understand the mechanisms that contribute to insulin dysregulation. The higher risk for metabolic syndrome imparted by antipsychotic medication use highlights one such mechanism. Though there is great variation in the number and types of signaling pathways targeted by these medications, the one common mechanism of action is through dopamine. Dopamine's effects on insulin signaling begin at the level of insulin secretion from the pancreas and continue through the central nervous system. In a reciprocal fashion, insulin also affects dopamine signaling, with specific effects on dopamine reuptake from the synapse. This review probes the dopamine-insulin connection to provide a comprehensive examination of how antipsychotics may contribute towards insulin resistance.

Abbreviations Used: D2R, dopamine receptor; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; DARPP-32, dopamine and cAMP-regulated phosphoprotein; PP1, protein phosphatase 1; MEK, mitogen-activated protein kinase/ERK kinase; ERK, extracellular-signal regulated kinase; DAT, dopamine transporter; GIRK, G-protein-gated inwardly-rectifying potassium channel; CAMKII, calcium/calmodulin-dependent kinase II; Akt, protein kinase B; PP2A, protein phosphatase 2A; GSK-3, glycogen synthase kinase-3; DA, dopamine; IRS, insulin receptor substrate protein; PI3K, phosphoinositol-kinase; PDK1, phosphoinositide-dependent kinase 1; Grb2, growth factor receptor-bound protein 2; Sos, son of sevenless.

Download English Version:

<https://daneshyari.com/en/article/5512689>

Download Persian Version:

<https://daneshyari.com/article/5512689>

[Daneshyari.com](https://daneshyari.com)